Contemporaneous Risk Factors for Visual Acuity in Non-Infectious Uveitis.


Journal

Ocular immunology and inflammation
ISSN: 1744-5078
Titre abrégé: Ocul Immunol Inflamm
Pays: England
ID NLM: 9312169

Informations de publication

Date de publication:
18 Aug 2021
Historique:
pubmed: 24 2 2021
medline: 26 2 2022
entrez: 23 2 2021
Statut: ppublish

Résumé

We evaluated the associations of clinical and demographic characteristics with visual acuity (VA) with over 5 years in a subspecialty noninfectious uveitis population. Retrospective data from 5,530 noninfectious uveitis patients were abstracted by expert reviewers, and contemporaneous associations of VA with demographic and clinical factors were modeled. Patients were a median of 41 years old, 65% female, and 73% white. Eyes diagnosed ≥5 years prior to cohort entry had worse VA (-1.2 lines) than those diagnosed <6 months prior, and eyes with cataract surgery performed prior to entry had worse VA (-5.9 lines) than those performed during follow-up. Vitreous haze (-4.2 lines for 3+ vs quiet), hypotony (-2.5 lines for ≤5 mm Hg vs 6-23 mm Hg), and CNV (-1.8 lines) all were strongly associated with reduced VA. Factors associated with reduced VA included well-known structural complications, and lack of subspecialty care during cataract surgery.

Identifiants

pubmed: 33621148
doi: 10.1080/09273948.2020.1828493
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1056-1063

Commentaires et corrections

Type : CommentIn

Auteurs

Maxwell Pistilli (M)

and the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group** Department of Ophthalmology, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.

Sapna S Gangaputra (SS)

Department of Ophthalmology and Vision Sciences, Vanderbilt Eye Institute, Nashville, Tennessee, USA.

Siddharth S Pujari (SS)

Om Eye Care Hospital, Belgaum, India.

Douglas A Jabs (DA)

Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Grace A Levy-Clarke (GA)

Laboratory of Immunology, National Eye Institute, Bethesda, Maryland, USA.
Tampa Bay Uveitis Center, Tampa, Florida, USA.

Robert B Nussenblatt (RB)

Laboratory of Immunology, National Eye Institute, Bethesda, Maryland, USA.

James T Rosenbaum (JT)

Department of Ophthalmology, Oregon Health and Science University, Portland, Oregon, USA.
Department of Medicine, Oregon Health and Science University, Portland, Oregon, USA.

H Nida Sen (HN)

Laboratory of Immunology, National Eye Institute, Bethesda, Maryland, USA.

Eric B Suhler (EB)

Department of Ophthalmology, Oregon Health and Science University, Portland, Oregon, USA.
Department of Medicine, Oregon Health and Science University, Portland, Oregon, USA.
Portland Veteran's Affairs Medical Center, Portland, Oregon, USA.

Jennifer E Thorne (JE)

Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Nirali P Bhatt (NP)

and the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group** Department of Ophthalmology, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.

C Stephen Foster (CS)

Massachusetts Eye Research and Surgery Institution, Cambridge, Massachusetts, USA.
Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA.

Hosne Begum (H)

Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Tonetta D Fitzgerald (TD)

and the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group** Department of Ophthalmology, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.

Kurt A Dreger (KA)

and the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Research Group** Department of Ophthalmology, The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

John H Kempen (JH)

Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA.
Department of Ophthalmology, Massachusetts Eye and Ear, Boston, Massachusetts, USA.
MCM Eye Unit, MCM General Hospital and MyungSung Medical School, Addis Ababa, Ethiopia, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH